Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Analysts flagged FTC scrutiny risk given the overlap between Alexion's complement franchise and Achillion's pipeline, but viewed the oral Factor D mechanism as…
The acquisition expands Alexion's rare-disease portfolio with first-generation oral Factor D danicopan plus a next-gen follow-on, addressing residual…
FDA approved Voydeya (danicopan) as an add-on to ravulizumab or eculizumab for adults with PNH and clinically significant extravascular hemolysis, validating…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Alexion acquired Achillion for $6.30 per share (~$930M initial cash consideration) plus non-tradeable CVRs of up to $2.00 per share — $1.00 on FDA approval of danicopan and $1.00 on ACH-5228 (danicopan follow-on) Phase 3 initiation (~$300M maximum). The deal added Achillion's oral Factor D inhibitor portfolio targeting complement-mediated rare diseases (PNH, C3 glomerulopathy) and closed January 28, 2020. The thesis was validated: the FDA approved the lead asset, danicopan (Voydeya), on March 29, 2024 as an add-on to ravulizumab or eculizumab for clinically significant extravascular hemolysis in adults with PNH. By then Alexion had itself been acquired by AstraZeneca (completed July 21, 2021), so Voydeya commercialized under AstraZeneca's Alexion Rare Disease unit.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Alexion Pharmaceuticals Inc. / Achillion Pharmaceuticals, Inc. (this deal) | 2019 | $1.2B | — |
| Alexion Pharmaceuticals Inc. / Synageva BioPharma | 2015 | $8.4B | 36 |
| Alexion Pharmaceuticals Inc. / Wilson Therapeutics AB | 2018 | $855M | 20 |
| Alexion Pharmaceuticals Inc. / Syntimmune, Inc. | 2018 | $1.2B | 14 |
| Alexion Pharmaceuticals Inc. / Portola Pharmaceuticals, Inc. | 2020 | $1.4B | — |
| Horizon Pharma plc / Crealta Holdings LLC | 2015 | $510M | 87 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2019 deals · Alexion Pharmaceuticals Inc. deals · Nephrology deals